INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Bellerophon
Therapeutics, Inc. (“Bellerophon” or the “Company”) (NASDAQ: BLPH) concerning the Company and its officers’ possible violations of federal securities laws.
Bellerophon is a clinical-stage therapeutics company that focuses on the development of products at the intersection of drugs
and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.
On February 13, 2015, Bellerophon sold 13 million shares of stock in its initial public stock offering (the "IPO"). Since
the IPO however, shares of Bellerophon stock have fallen sharply, after the Company reported poor operating results and certain
executive changes.
If you purchased Bellerophon securities, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of
Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005701/en/